Pemtumomab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Mouse |
| Target | MUC1 |
| Clinical data | |
| Trade names | Theragyn |
| Routes of administration | Intraperitoneal |
| Identifiers | |
| ATC code | None |
| ChemSpider | none |
  (what is this?) (verify) | |
Pemtumomab (trade name Theragyn) is a mouse monoclonal antibody used to treat cancer. The substance has affinity to various types of cancer, like ovarian cancer and peritoneal cancer, via the polymorphic epithelial mucin (PEM or MUC-1) and delivers the radioisotope Yttrium-90 into the tumour.[1] As of 2009, it is undergoing Phase III clinical trials.[2]
It has been granted orphan drug status in Europe.[3]
References
- ↑ Oei, AL; Moreno, M; Verheijen, RH; Sweep, FC; Thomas, CM; Massuger, LF; Von Mensdorff-Pouilly, S (2008). "Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer". International Journal of Cancer. Journal International Du Cancer 123 (8): 1848–53. doi:10.1002/ijc.23725. PMID 18661524.
- ↑ ClinicalTrials.gov
- ↑ Antisoma's Lead Product, Pemtumomab Granted European Orphan Drug Status
This article is issued from Wikipedia - version of the Thursday, November 19, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.